ATE88895T1 - Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel. - Google Patents

Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.

Info

Publication number
ATE88895T1
ATE88895T1 AT90101570T AT90101570T ATE88895T1 AT E88895 T1 ATE88895 T1 AT E88895T1 AT 90101570 T AT90101570 T AT 90101570T AT 90101570 T AT90101570 T AT 90101570T AT E88895 T1 ATE88895 T1 AT E88895T1
Authority
AT
Austria
Prior art keywords
acid
therapy
controlled release
manufacture
same way
Prior art date
Application number
AT90101570T
Other languages
English (en)
Inventor
Grazie Christina Le
Original Assignee
Bioresearch Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioresearch Spa filed Critical Bioresearch Spa
Application granted granted Critical
Publication of ATE88895T1 publication Critical patent/ATE88895T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT90101570T 1989-01-31 1990-01-26 Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel. ATE88895T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8919261A IT1229517B (it) 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.

Publications (1)

Publication Number Publication Date
ATE88895T1 true ATE88895T1 (de) 1993-05-15

Family

ID=11156204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90101570T ATE88895T1 (de) 1989-01-31 1990-01-26 Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.

Country Status (9)

Country Link
US (1) US5538734A (de)
EP (1) EP0382019B1 (de)
JP (1) JPH0757727B2 (de)
AT (1) ATE88895T1 (de)
DE (1) DE69001493T2 (de)
DK (1) DK0382019T3 (de)
ES (1) ES2055175T3 (de)
GR (1) GR3007790T3 (de)
IT (1) IT1229517B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
DK0877563T3 (da) 1996-01-31 2004-07-26 Univ South Alabama Levnedsmiddel- og vitaminpræparater, der indeholder den naturlige isomer af reducerede folater
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
PT1071425E (pt) * 1998-04-24 2007-11-16 Scarista Ltd ''tratamento da depressão e composições farmacêuticas para o efeito''
WO2000007566A1 (en) * 1998-08-03 2000-02-17 Epigenesis Pharmaceuticals, Inc. A new analgesic, anti-inflammatory and wound healing agent
CA2348693C (en) * 1998-10-19 2008-07-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
CA2348390C (en) * 1998-10-30 2008-11-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions for the treatment and prevention of neurological and pathopsychological diseases
WO2002083151A2 (en) * 2000-12-14 2002-10-24 Tufts University Compositions and methods for treating an arthritic condition
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
WO2002085297A2 (en) * 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
CN100540007C (zh) * 2002-06-17 2009-09-16 埃匹吉尼斯医药有限公司 二水合脱氢表雄酮和采用其组合物治疗哮喘或慢性阻塞性肺部疾病的方法
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
IL256966B2 (en) 2009-07-10 2023-12-01 O Scott Linzy Iii Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates
CA2825428C (en) 2010-02-12 2022-06-14 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
US11110113B2 (en) 2016-11-03 2021-09-07 Gentelon, Inc. Compositions and methods for treating depression
EP3609894A1 (de) 2017-03-31 2020-02-19 Merck Patent GmbH Kristallines natriumsalz der 5-methyl-(6s)-tetrahydrofolsäure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572137A (en) * 1977-02-22 1980-07-23 Bioresearch Sas Del Dr Livio C Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
GB2072504B (en) * 1980-03-27 1983-10-26 Coppen A J Pharmaceutical compositions
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.

Also Published As

Publication number Publication date
EP0382019B1 (de) 1993-05-05
JPH02240021A (ja) 1990-09-25
EP0382019A1 (de) 1990-08-16
GR3007790T3 (de) 1993-08-31
ES2055175T3 (es) 1994-08-16
IT8919261A0 (it) 1989-01-31
US5538734A (en) 1996-07-23
DE69001493T2 (de) 1993-08-26
JPH0757727B2 (ja) 1995-06-21
DK0382019T3 (da) 1993-06-07
IT1229517B (it) 1991-09-03
DE69001493D1 (de) 1993-06-09

Similar Documents

Publication Publication Date Title
ATE88895T1 (de) Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.
ATE97809T1 (de) Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe und wirksam in der therapie organisch mentaler stoerungen sowie die entsprechenden arzneimittel.
IL104006A (en) Azaheterocyclylmethyl-chromans their preparation and pharmaceutical compositions containing them
FI862011A0 (fi) Terapeutiska nukleosider.
ATE126433T1 (de) Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.
EP1327452A3 (de) Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und SS-Mimetika
DE59000270D1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
IL85228A (en) 1-(4-hydroxy-3,5-di-tert.- butylbenzoyl) homopiperazine, various derivatives thereof, processes for the preparation of these and pharmaceutical compositions containing them
DE69005860T2 (de) Verwendung von 5'-Deoxy-5'-methylthioadenosin S-adenosylmethionin und dessen Salzen zur Herstellung von Seborrhea vermindernden Arzneimitteln.
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE69217511T2 (de) Pyridazindionderivate, ihre Herstellung und Verwendung als Arzneimittel
ATE184485T1 (de) Verwendung der 1-4-4-aryl(oder heteroaryl)-1- piperazinylbutyl-1h-azol-derivate zur herstellung von arzneimitteln zur behandlung der störungen der magensekretion
IT1240683B (it) Composizione farmaceutica contenente egf
IL104005A0 (en) Piperidylmethyl-substituted chroman derivatives,their preparation and pharmaceutical compositions containing them
US5378844B1 (en) 8-(1-aminocycloalkyl)-1,3-dialkylxanthine derivatives preparation process and antidepressant nootropic and psychostimulant composition thereof
DE3577443D1 (de) Derivate von dihydroorotsaeure, deren verfahren zur herstellung und deren pharmazeutische zusammensetzungen.
ES2070934T3 (es) Derivados de oxotremorina 3- o 4-sustituidos.
ATE65408T1 (de) Arzneimittel enthaltend in kombination interferon und 1-desoxy-piperidinosen, verfahren zu deren herstellung und deren verwendung.
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
ATE106874T1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NO890261D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridin-derivater.
ATE53384T1 (de) 3-mercapto-2-oxo-1-pyrrolidinessigsaeurederivate verfahren zur herstellung und pharmazeutische zusammensetzungen die sie enthalten.

Legal Events

Date Code Title Description
EEFA Change of the company name
EELA Cancelled due to lapse of time